Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
MeSH Number(s)
E02.183.750.500
E02.319.077.500
E02.319.310.037
Concept/Terms
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Drug Combinations, Antineoplastic
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
- Combined Antineoplastic Agents
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Combined Chemotherapy Regimens
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Chemotherapy Protocols, Antineoplastic
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 37 | 32 | 69 |
| 1994 | 43 | 18 | 61 |
| 1995 | 41 | 17 | 58 |
| 1996 | 56 | 23 | 79 |
| 1997 | 55 | 17 | 72 |
| 1998 | 71 | 24 | 95 |
| 1999 | 60 | 31 | 91 |
| 2000 | 61 | 25 | 86 |
| 2001 | 60 | 22 | 82 |
| 2002 | 71 | 31 | 102 |
| 2003 | 77 | 41 | 118 |
| 2004 | 87 | 39 | 126 |
| 2005 | 105 | 41 | 146 |
| 2006 | 116 | 57 | 173 |
| 2007 | 105 | 50 | 155 |
| 2008 | 115 | 61 | 176 |
| 2009 | 138 | 59 | 197 |
| 2010 | 153 | 55 | 208 |
| 2011 | 150 | 73 | 223 |
| 2012 | 165 | 63 | 228 |
| 2013 | 165 | 72 | 237 |
| 2014 | 200 | 100 | 300 |
| 2015 | 203 | 83 | 286 |
| 2016 | 183 | 95 | 278 |
| 2017 | 178 | 102 | 280 |
| 2018 | 238 | 77 | 315 |
| 2019 | 276 | 94 | 370 |
| 2020 | 225 | 135 | 360 |
| 2021 | 185 | 160 | 345 |
| 2022 | 42 | 203 | 245 |
| 2023 | 1 | 6 | 7 |
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Hematology. 2023 Dec; 28(1):2156731.
-
Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics. 2023 Feb; 43(2):e220103.
-
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. Oncologist. 2023 Jan 18; 28(1):72-79.
-
Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma. JAMA. 2023 01 17; 329(3):261.
-
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. Blood Cancer J. 2023 Jan 11; 13(1):11.
-
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 03; 6(1):e2249720.
-
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 Feb; 98(2):300-308.
-
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 01 05; 388(1):44-54.
-
Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study. BMC Cancer. 2022 Dec 20; 22(1):1331.
-
The Evolving Role of Radiation Therapy in DLBCL: From Early-Stage to Refractory Disease. Oncology (Williston Park). 2022 12 20; 36(12):718-727.